LabCorp Announces 2019 Fourth Quarter and Full Year Results and Provides 2020 Guidance

Revenue: Q4 of $3.0 billion , up 6% over 2018; Full year of $11.6 billion , up 2% over 2018 Diluted EPS: Q4 of $2.32 , up from $1.56 last year; Full year of $8.35 , down from $8.61 last year Adjusted EPS: Q4 of $2.86 , up 13% over 2018; Full year of $11.32 , up 3% over 2018 Free Cash Flow: Q4 of

LabCorp Earns 100 Percent on Human Rights Campaign Foundation’s Annual Scorecard on LGBTQ Workplace Equality

Receives Designation as a Best Place to Work for LGBTQ Equality For Third Consecutive Year BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 21, 2020-- LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that it received a perfect

LabCorp to Adopt Thermo Fisher Scientific’s Ion Torrent Genexus Next-Generation Sequencing System and Pan-Cancer Assay for Use in Oncology Research and Development

BURLINGTON, N.C. & CARLSBAD, Calif. --(BUSINESS WIRE)--Jan. 14, 2020-- LabCorp® (NYSE: LH) announced it will adopt the Ion Torrent Genexus System* and Oncomine Precision Assay* for use in research and development of companion diagnostics as well as other future oncology and precision medicine